View Older Stories
-
Scholar Rock resubmits drug application to FDA for SMA treatment
-
Truist Securities on Scholar Rock (SRRK): today's Roche news 'neutral to positive'
-
BMO Capital on Scholar Rock (SRRK): emugrobart discontinuation a 'strong positive'
-
Cantor Fitzgerald: 'We now expect apitegromab to have near complete market share'
-
Scholar Rock (SRRK) PT Raised to $50 at JPMorgan
-
'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler
-
Scholar Rock (SRRK) PT Raised to $50 at Leerink Partners
-
Scholar Rock (SRRK) PT Raised to $53 at Barclays
-
Scholar Rock (SRRK) PT Raised to $55 at Truist Securities
-
Raymond James Reiterates Strong Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock (SRRK) PT Raised to $70 at BMO Capital
-
Scholar Rock Holding Corp. (SRRK) Tops Q4 EPS by 2c
-
Scholar Rock (SRRK) PT Raised to $58 at H.C. Wainwright
-
Scholar Rock targets 2026 apitegromab BLA resubmission and launch
-
Citi Starts Scholar Rock (SRRK) at Buy
-
UBS Starts Scholar Rock (SRRK) at Buy
-
Scholar Rock's (SRRK) Apitegromab Approval Certain - Cantor Fitzgerald
-
Wolfe Research Starts Scholar Rock (SRRK) at Outperform
-
Scholar Rock (SRRK) PT Raised to $50 at BMO Capital
-
Scholar Rock Holding Corp. (SRRK) Misses Q3 EPS by 6c
-
Scholar Rock (SRRK) PT Lowered to $44 at Truist Securities
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock stock falls after FDA flags issues at manufacturing facility
-
BofA Securities Starts Scholar Rock (SRRK) at Buy
-
Truist on Scholar Rock (SRRK): 'We See Today's Stock Weakness as a Buying Opportunity'
-
Scholar Rock (SRRK) PT Lowered to $51 at Piper Sandler
-
Scholar Rock (SRRK) PT Lowered to $44 at H.C. Wainwright
-
Scholar Rock (SRRK) PT Lowered to $48 at Leerink Partners
-
Scholar Rock (SRRK) PT Lowered to $44 at Barclays
-
FDA rejects Scholar Rock's apitegromab application due to facility issues
-
Scholar Rock Holding Corp. (SRRK) Halted, News Pending
-
Barclays Starts Scholar Rock (SRRK) at Overweight
-
Leerink Partners Starts Scholar Rock (SRRK) at Outperform
-
Jefferies Assumes Scholar Rock (SRRK) at Buy
-
Raymond James Adjusts Analysts Current Favorites List
-
Scholar Rock (SRRK) PT Lowered to $45 at BMO Capital
-
Raymond James Reiterates Strong Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock Holding Corp. (SRRK) Misses Q2 EPS by 32c
-
Raymond James Assumes Scholar Rock (SRRK) at Strong Buy
-
Cantor Fitzgerald Starts Scholar Rock (SRRK) at Overweight
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
H.C. Wainwright Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock Holding (SRRK) Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
Scholar Rock Holding Corp. (SRRK) Appoints as Rebecca McLeod Chief Brand Officer and U.S. General Manager
-
Scholar Rock Holding Corp. (SRRK) Misses Q1 EPS by 1c
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock Holding Corp. (SRRK) Appoints David L. Hallal as CEO
-
Piper Sandler: 'Scholar Rock (SRRK) Shares are Significantly Undervalued'
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'

